TY - JOUR
T1 - Myeloid Cells and Chronic Liver Disease
T2 - a Comprehensive Review
AU - Lian, Min
AU - Selmi, Carlo F
AU - Gershwin, M. Eric
AU - Ma, Xiong
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Myeloid cells play a major role in the sensitization to liver injury, particularly in chronic inflammatory liver diseases with a biliary or hepatocellular origin, and the interplay between myeloid cells and the liver may explain the increased incidence of hepatic osteodystrophy. The myeloid cell-liver axis involves several mature myeloid cells as well as immature or progenitor cells with the complexity of the liver immune microenvironment aggravating the mist of cell differentiation. The unique positioning of the liver at the junction of the peripheral and portal circulation systems underlines the interaction of myeloid cells and hepatic cells and leads to immune tolerance breakdown. We herein discuss the scenarios of different chronic liver diseases closely modulated by myeloid cells and illustrate the numerous potential targets, the understanding of which will ultimately steer the development of solid immunotherapeutic regimens. Ultimately, we are convinced that an adequate modulation of the liver microenvironment to modify the functional and quantitative characteristics of myeloid cells will be a successful approach to treating chronic liver diseases of different etiologies.
AB - Myeloid cells play a major role in the sensitization to liver injury, particularly in chronic inflammatory liver diseases with a biliary or hepatocellular origin, and the interplay between myeloid cells and the liver may explain the increased incidence of hepatic osteodystrophy. The myeloid cell-liver axis involves several mature myeloid cells as well as immature or progenitor cells with the complexity of the liver immune microenvironment aggravating the mist of cell differentiation. The unique positioning of the liver at the junction of the peripheral and portal circulation systems underlines the interaction of myeloid cells and hepatic cells and leads to immune tolerance breakdown. We herein discuss the scenarios of different chronic liver diseases closely modulated by myeloid cells and illustrate the numerous potential targets, the understanding of which will ultimately steer the development of solid immunotherapeutic regimens. Ultimately, we are convinced that an adequate modulation of the liver microenvironment to modify the functional and quantitative characteristics of myeloid cells will be a successful approach to treating chronic liver diseases of different etiologies.
KW - Chronic inflammatory liver diseases
KW - Hepatic osteodystrophy
KW - Myeloid cell
KW - Myeloid cell-liver axis
UR - http://www.scopus.com/inward/record.url?scp=85044668319&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044668319&partnerID=8YFLogxK
U2 - 10.1007/s12016-017-8664-x
DO - 10.1007/s12016-017-8664-x
M3 - Review article
C2 - 29313221
AN - SCOPUS:85044668319
VL - 54
SP - 307
EP - 317
JO - Clinical Reviews in Allergy and Immunology
JF - Clinical Reviews in Allergy and Immunology
SN - 1080-0549
IS - 2
ER -